MIU Activated to Participate in Water Vapor Ablation Clinical Trial for Treatment of Prostate Cancer

Michigan Institute of Urology (MIU), one of the longest-standing and largest sub-specialty urology practices in Southeast Michigan, has been activated as a clinical trial site for Francis Medical’s interventional study on water vapor ablation for localized intermediate-risk prostate cancer.

The purpose of the VAPOR 2 study is to evaluate the safety and efficacy of a device called the Vanquish™ System, which uses water vapor ablation therapy to destroy prostate cancer cells. Water vapor ablation uses the thermodynamic properties of high-temperature water vapor as it condenses back to a liquid state to deliver targeted energy to kill cancer cells in the prostate. It is a minimally invasive outpatient procedure.

MIU is the only site selected in Michigan to participate in the second clinical trial of the device currently.

“MIU is committed to offering our patients the latest technology. VAPOR 2 represents an investigational study to evaluate an alternative therapy in the treatment of prostate cancer that allows us to treat only the portion of the prostate impacted by cancer rather than the entire prostate gland. The goal is to treat cancer effectively while minimizing the side effects on a man’s urinary, sexual, and bowel functions. The VAPOR 2 study will assess the ability of water vapor technology to focally destroy a tumor and the efficacy of this cancer treatment,” said MIU Director of Research Dr. Ken Kernen.

To learn more about participation criteria and the study plan, patients and physicians should visit ClinicalTrials.gov to review the study record or contact Danielle Osterhout at (248) 786-0467 or email osterhoutd@michiganurology.com.